- Home
- MRSN vs RCAT Comparison
MRSN vs RCAT Comparison
Compare MRSN & RCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- RCAT
- Stock Information
- Founded
- MRSN 2001
- RCAT 2002
- Country
- MRSN United States
- RCAT United States
- Employees
- MRSN N/A
- RCAT N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- RCAT Wholesale Distributors
- Sector
- MRSN Health Care
- RCAT Industrials
- Exchange
- MRSN Nasdaq
- RCAT Nasdaq
- Market Cap
- MRSN 230.0M
- RCAT 248.8M
- IPO Year
- MRSN 2017
- RCAT 2017
- Fundamental
- Price
- MRSN $2.21
- RCAT $4.70
- Analyst Decision
- MRSN Buy
- RCAT Strong Buy
- Analyst Count
- MRSN 6
- RCAT 1
- Target Price
- MRSN $6.00
- RCAT $4.00
- AVG Volume (30 Days)
- MRSN 1.1M
- RCAT 1.5M
- Earning Date
- MRSN 11-13-2024
- RCAT 12-13-2024
- Dividend Yield
- MRSN N/A
- RCAT N/A
- EPS Growth
- MRSN N/A
- RCAT N/A
- EPS
- MRSN N/A
- RCAT N/A
- Revenue
- MRSN $34,837,000.00
- RCAT $18,864,788.00
- Revenue This Year
- MRSN N/A
- RCAT $125.67
- Revenue Next Year
- MRSN $7.15
- RCAT N/A
- P/E Ratio
- MRSN N/A
- RCAT N/A
- Revenue Growth
- MRSN N/A
- RCAT 259.85
- 52 Week Low
- MRSN $1.22
- RCAT $0.53
- 52 Week High
- MRSN $6.28
- RCAT $5.01
- Technical
- Relative Strength Index (RSI)
- MRSN 51.26
- RCAT 75.13
- Support Level
- MRSN $2.12
- RCAT $3.79
- Resistance Level
- MRSN $2.83
- RCAT $4.22
- Average True Range (ATR)
- MRSN 0.24
- RCAT 0.33
- MACD
- MRSN 0.03
- RCAT 0.12
- Stochastic Oscillator
- MRSN 39.81
- RCAT 84.88
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About RCAT Red Cat Holdings Inc.
Red Cat Holdings Inc is a military technology company that integrates robotic hardware and software to provide critical situational awareness and actionable intelligence to on-the-ground warfighters and battlefield commanders. Its mission is to enhance the effectiveness and safety of military operations domestically and globally. Red Cat's suite of solutions includes Teal Drones, developer of the Golden Eagle, a small unmanned system with the highest resolution imaging for night-time operations, and Skypersonic, a provider of unmanned aircraft for interior spaces and other dangerous environments.